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Summary
Objective: We aimed to investigate whether the Prognos®
device might be a useful tool in the diagnosis of disorders
suspected to be due to dental amalgam fillings. Participants
and Methods: A diagnostic case-control study was per-
formed in 27 patients who complained about health prob-
lems attributed to amalgam (cases), 27 healthy volunteers
with amalgam fillings (controls I), and 27 healthy amalgam-
free volunteers (controls II). All participants were tested be-
fore and after application of 300 mg DMPS (2.3-dimercapto-
1-propanesulfonic acid) with Prognos®, a diagnostic device
for the energetic measurement of Traditional Chinese Medi-
cine meridians. In addition, mercury was measured in
blood, urine, and saliva, and a lymphocyte transformation
test (LTT) was performed. Results: Diagnoses derived from
the first and second Prognos® testing did not agree above
chance (Cohen’s Kappa = –0.11, 95% confidence interval
–0.33 to 0.10; p = 0.30). Agreement for secondary outcome
measures was poor, too. Prognos® measurements did not
differ between cases and controls. Correlations with mea-
surements in urine, blood and saliva were low. Conclusion:
In this study Prognos® could not be shown to be a useful
tool in the diagnosis of disorders suspected to be due to
dental amalgam fillings. 
Schlüsselwörter 
Prognos® · Elektroakupunktur · Komplementärmedizin ·
Amalgam · Nebenwirkungen · Quecksilber
Zusammenfassung
Prognos® in der Diagnose einer Amalgam-Überempfind-
lichkeit – eine diagnostische Fall-Kontroll-Studie
Fragestellung: In dieser Studie sollte untersucht werden, ob
das Prognos®-Messgerät ein geeignetes diagnostisches In-
strument beim Verdacht auf amalgambedingte Erkrankun-
gen ist. Teilnehmer und Methoden: Eine diagnostische Fall-
Kontroll-Studie wurde an 27 Patienten, die ihre gesundheit-
lichen Beschwerden auf Amalgamfüllungen zurückführten
(Fälle), 27 gesunden Amalgamträgern (Kontrollgruppe I)
und 27 gesunden amalgamfreien Teilnehmern (Kontroll-
gruppe II) durchgeführt. Alle Teilnehmer wurden jeweils vor
und nach Einnahme von 300 mg DMPS (2,3-Dimercapto-1-
Propansulfonsäure) mit dem Prognos®-Messgerät, das den
Energiezustand der Meridiane gemäß der Traditionellen Chi-
nesischen Medizin misst, untersucht. Weiterhin wurden
Quecksilber in Blut, Urin und Speichel gemessen sowie ein
Lymphozytentransformationstest (LTT) durchgeführt. Ergeb-
nisse: Die Diagnosen der ersten und zweiten Prognos®-Mes-
sung stimmten nicht überzufällig überein (Cohens Kappa =
–0,11, 95%-Konfidenzinterval –0,33 bis 0,10; p = 0,30). Die
Reliabilität der Ergebnisse der Einzelsubstanzmessungen
war ebenfalls gering. Die Ergebnisse der Prognos®-Messun-
gen unterschieden sich nicht signifikant zwischen Be-
schwerdeträgern und Kontrollen. Die Ergebnisse der Pro-
gnos®-Messungen korrelierten nicht oder nur in geringem
Ausmaß mit denen der Messungen in Urin, Blut und Spei-
chel. Schlussfolgerung: Die Ergebnisse der vorliegenden
Studie sprechen nicht dafür, dass das Prognos®-Testgerät
für die Diagnostik von vermutlich amalgambedingten Be-
schwerden geeignet ist. 
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Introduction
There is considerable discussion whether amalgam dental fill-
ings can cause diseases or not. So far there is no convincing
evidence from epidemiological, toxicological or immunologi-
cal research that ‘amalgam burden’ or ‘amalgam hypersensi-
tivity’ (beyond rare cases of proven allergic reactions like oral
lichenoid reactions) are valid pathological concepts [1, 2].
Nevertheless many patients and physicians are convinced that
amalgam is hazardous to health [3, 4]. 
In 1996, a group of about 1,500 patients who attributed their
chronic complaints to amalgam fillings filed a lawsuit against
Degussa, the major German manufacturer of this material. A
settlement was reached in which the manufacturer agreed to
sponsor an independent research program (German Amal-
gam Trial = GAT) which was administrated by an indepen-
dent research funding body (Stifterverband für die Deutsche
Wissenschaft). Several studies were performed to investigate
(a) the risks associated with dental amalgam fillings; (b) diag-
nostic procedures possibly adequate to verify amalgam hyper-
sensitivity; (c) potential therapies. The study on hand is focus-
ing on common diagnostic methods to investigate a possible
amalgam burden. 
A device frequently used by practitioners of complementary
and alternative medicine is the Prognos® instrument. The de-
vice was originally developed for the Russian space program
to monitor the health status of cosmonauts and, if necessary,
to intervene therapeutically [5]. On the diagnostic level, Prog-
nos® aims to provide a comprehensive energetic assessment
within the framework of Traditional Chinese Medicine (TCM)
concepts. The electric skin resistance at terminal meridian
points at fingers and toes is measured [6, 7]. Using a software
program a variety of findings on the energetic status of merid-
ians and the organism is derived. We investigated (1) whether
there is agreement between the diagnostic findings of the
Prognos® device related to amalgam hypersensitivity obtained
at two separate sessions; (2) whether they correlate with other
tests used in the diagnosis of amalgam hypersensitivity; (3)
whether the findings of Prognos® and other diagnostic tests
differ between patients with suspected amalgam hypersensi-
tivity, healthy amalgam bearers, and healthy amalgam-free
volunteers.
Methods
Design and Participants
The study used a case-control design with two control groups. Group 1
consisted of 27 patients (cases) fulfilling the following criteria: symptoms
attributed (by patients and/or care providers) to amalgam fillings; ≥10
symptoms (≥3 with severe intensity) from a list of 50 symptoms (with a
rating scale of 0 = not present to 3 = severe; single items were added to a
symptom score), commonly reported by patients with amalgam hypersen-
sitivity [8]; ≥5 amalgam surfaces; age 20–65 years. All patients underwent
a thorough medical examination to rule out relevant comorbidity. Group
2 (healthy amalgam bearers, controls I) consisted of 27 healthy (according
to history and clinical findings) volunteers between 20 and 65 years with
≥5 amalgam surfaces. Group 3 (healthy amalgam-free individuals, con-
trols II) consisted of 27 healthy volunteers who were free of and never
had any amalgam fillings and who did not have any known specific mer-
cury or amalgam exposure. Volunteers with >7 mild symptoms on the list
of 50 symptoms were not included in groups 2 and 3.
Participants for group 1 were recruited out of a pool of applicants for a
therapeutic study which was advertised in local newspapers. In this thera-
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Fig. 1. Flow chart of testings.
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Fig. 2. Comparison of Prognos® sum scores in the first and the second
session. z = Amalgam hypersensitive participants, ▲ healthy amalgam
participants, ✴ healthy amalgam-free participants.
peutic study, participants were included if they had only amalgam as den-
tal fillings or in combination with composite. Participation in the diagnos-
tic study described here was offered to all other applicants with additional
dental fillings like gold, metal or ceramics, if they fulfilled all necessary
criteria mentioned above. Healthy control participants were recruited
from local universities by advertisements on bulletin boards. All partici-
pants received oral and written information on the study and gave in-
formed consent. The study protocol was approved by the ethics commit-
tee of the Medical Faculty of the Technische Universität München, Ger-
many.
Measurements
All study participants underwent the same set of tests in the same chrono-
logical order (fig. 1). On the first visit: Prognos® session 1, one blood sam-
pling for a lymphocyte transformation test (LTT), one blood sampling for
measuring mercury in plasma and red blood cells, and finally saliva sam-
pling for measuring mercury. 48 h before the second visit all participants
had to start a 24-hour collection of urine at home. Then 300 mg Dimaval®
(Heyl; Berlin, Germany) had to be taken orally and urine was collected
for another 24 hours until the morning of the 2nd Prognos® testing when
all urine samples were returned. All biological samples were blinded and
either transferred to the relevant examiner within 10 hours or frozen.
Measurements of mercury in blood, urine and saliva were performed in a
cold vapor atomic absorption spectrometer. All printouts of Prognos®
testings were blinded and sent to a Prognos® expert.
This manuscript focuses on methods and results for the Prognos® testing.
Details on the methods and results of the other diagnostic tests used in
this study will be published separately.
Prognos® test. A Prognos® instrument and software (V 4.12) were kindly
provided by the manufacturer (Medprevent GmbH and Co; Nagel, Ger-
many). Prognos® testing is based on the hypothesis of EAV (elec-
troacupuncture according to Voll). The patient is included in a low-cur-
rent electric circuit and tested with different ‘offending’ substances. It is
assumed that these substances have typical electromagnetic frequencies
that produce measurable variations of the cutaneous electric potential.
Changes are measured at the terminal points of the meridians where the
electrical conductance is particularly high.
According to the manufacturer of Prognos® a clear correlation exists be-
tween the skin resistance and the energy supply; the higher the resistance
value (kΩ, kiloohm) the less favorable is the energetic supply of the
meridian and vice versa [9]. Because of these principles Prognos® is used
both as a diagnostic device and to verify a therapy. 
In our study all participants were tested twice for amalgam hypersensitiv-
ity in a standardized procedure on separate days. The testing was per-
formed by a researcher (WK) who had been trained by an expert of this
method until training and performance were considered adequate. The
same expert analyzed the measurements.
From all participants the resistances in kΩ were measured at the starting
and end points (finger and toe nails) of the 12 meridians. After a first
‘main’ measurement, a stimulation of acupuncture point LG20 with a de-
vice called bio comb was performed and a second ‘stimulated’ measure-
ment was recorded. To identify a possible amalgam hypersensitivity, a spe-
cial set of 6 substances (stored in small glass vessels) recommended by the
manufacturer of Prognos® was then used for comparative measurements:
Amalgam D10, Amalgam D200, Amalgam pure (same preparation as
used in dental practice), Chlorella, Coriander and Toxinex (liquid prepa-
ration of Derivatio H). These substances were held in one hand by the
participant while the examiner measured all meridian points on the oppo-
site side. Then glass vessel and measurements swapped sides and the re-
maining meridian points were measured. The software of the Prognos®
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Fig. 3. Prognos® sum scores in the 1st and 2nd session in amalgam hypersensitive participants, healthy amalgam participants and healthy amalgam-free
participants (median and quartiles).
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device set the first main measurement to zero as a bench mark for further
measurements. The following measurements were given as deviations in
percentage from this bench mark. The findings of the 6 substance tests
were combined in a sum score which was postulated to be sensitive for
amalgam hypersensitivity. Based on this sum score and the pattern of re-
sults the Prognos® expert made a dichotomized diagnostic conclusion. 
Lymphocyte transformation test (LTT). 20 ml of venous blood were taken
with a syringe pretreated with heparin, and another 10 ml of venous blood
in a syringe not pretreated. The laboratory which performed the LTT in
our study used a variation of the common LTT [10] in order to increase
sensitivity. To identify possible amalgam hypersensitivity a set of metals
was tested including inorganic mercury, methyl-, ethyl- and phenyl-mer-
cury, amalgam, copper, silver and tin. Out of this list amalgam and inor-
ganic mercury were predefined as the most specific test substances. 
Mercury in blood. 10 ml of venous blood were taken with a syringe (pre-
treated with EDTA). Plasma and red cells were separated by centrifuga-
tion. Mercury was determined in each fraction by cold vapor atomic ab-
sorption spectrometry. Inorganic and total mercury were measured in du-
plicates and the amount of organic mercury was determined by the sub-
traction of inorganic mercury means from total mercury means [11].
Mercury in urine and mercury mobilization. Between the first and the sec-
ond Prognos® testing, all participants had to collect urine for 24 hours be-
fore and for 24 hours after taking 300 mg tablets of Dimaval® orally at
home [12, 13]. Collection was done in 2.5 l polyethylene bottles containing
2 ml of 10% nitric acid to prevent reduction and volatilization of mercury.
Urine samples were handed in immediately after the second collection
when the participant returned for the second Prognos® testing. 
Saliva testing (chewing gum test). Simultaneous to the blood sampling a
chewing gum test was performed at the first interview [14]. All partici-
pants gave a spontaneous saliva sample of 5 ml (non activated saliva) and
another 5 ml after extensive use of a chewing gum (activated saliva). To
avoid excessive results special attention was given to thorough centrifuga-
tion in order to separate small particles of amalgam that may have been
collected accidentally in the sample.
Statistics
All data analysis was performed with SPSS® (Version 11.5, SPSS Inc.,
Chicago, IL, USA). Main outcome measures for the two parts (agreement
of findings obtained at two separate sessions; correlation testing) of the
study were defined beforehand. Main outcome measure of the first part
was agreement above chance (quantified by Cohen’s Kappa) for the di-
chotomized (amalgam burden yes/no) Prognos® test results of the two di-
agnostic sessions in each participant. As secondary outcomes we calculat-
ed Spearman correlation coefficients and intraclass correlation coeffi-
cients (ICC; 2-way mixed models) for the summary score and the 6 single
substance tests. Main outcome measure for the second part was the corre-
lation between the Prognos® sum score at the first session and a combina-
tion score for mercury in saliva after chewing gum and 24-hour urine after
mobilization with Dimaval®. This score was chosen on recommendation
of the Prognos® expert and calculated as follows: Findings from urine and
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Amalgam hypersensitive Healthy amalgam Healthy amalgam-free 
participants (n = 27) participants (n = 27) participants (n = 27)
Female 14 (52%) 16 (59%) 22 (82%)
Age (years) 40 (25–60) 28 (21–55) 23 (20–29)
Amalgam fillings 7 (3–17) 7 (3–16) –
Amalgam surfaces 14 (5–33) 12 (5–37) –
Symptom score 43 (28–78) 3 (0–7) 4 (0–7)
Number of symptoms at least mild 30 (20–37) 3 (0–7) 4 (0–7)
Number of symptoms at least moderate 10 (7–25) – –
Years since first amalgam filling 27 (13–40) 15 (2–35) –
Table 1. Characte-
ristics of participants:
values are absolute
numbers (percenta-
ges) or medians 
(ranges)
Amalgam hyper- Healthy amalgam Healthy amalgam- p-value
sensitive participants participants free participants
Prognos® first session (n = 76)
Sum score 47.83 (18.60) 49.38 (25.94) 52.04 (41.26) 0.83
Amalgam D10 –6.96 (11.42) –5.73 (18.33) 1.92 (12.33) 0.08
Amalgam D200 –2.96 (16.32) –4.96 (16.92) –8.65 (30.34) 0.89
Pure amalgam –3.08 (16.78) 0.73 (11.96) –2.31 (13.14) 0.58
Chlorella –0.21 (9.72) –1.50 (15.49) 0.81 (12.67) 0.90
Toxinex 1.04 (13.31) –4.04 (14.97) –5.04 (16.33) 0.60
Coriander –6.17 (15.15) –1.35 (13.74) 3.46 (17.65) 0.09
Prognos® second session (n = 73)
Sum score 55.35 (33.74) 57.32 (33.23) 50.00 (30.18) 0.70
Amalgam D10 –6.00 (21.60) –11.92 (25.38) –5.58 (21.87) 0.59
Amalgam D200 –2.95 (15.87) –0.16 (10.86) 0.88 (12.19) 0.76
Pure amalgam 0.55 (13.06) –5.56 (15.19) –6.15 (13.80) 0.05
Chlorella –0.84 (14.05) –1.92 (17.28) 1.23 (17.91) 0.96
Toxinex –3.32 (13.94) 3.56 (16.11) –0.73 (14.05) 0.53
Coriander 3.09 (12.83) –3.36 (15.65) –4.27 (15.94) 0.29
Table 2. Diagnostic
test results: values
are means (sd), 
p-values from
Kruskal-Wallis test 
saliva tests were ranked and divided in 10 groups of equal size. The 10%
participants with the highest values were allocated a score of 9, the next
10% a score of 8, and so on. The findings from the two tests were then
added resulting in the final score (range 0–18). We also calculated Spear-
man correlation coefficients for the single Prognos® measurements and
findings from blood, urine and saliva. Furthermore we tested whether di-
agnostic findings differed significantly between the groups both for the
summary score and for the 6 single substance tests (Kruskal-Wallis test
and Mann-Whitney U test). Finally correlation coefficients for diagnostic
findings in the different tests were calculated. 
Results
Table 1 summarizes the characteristics of the participants.
Cases tended to be older and less often females than controls.
Symptoms of patients were mostly unspecific. The four most
frequent symptoms regarding severity and quantity were: gen-
eral weakness, fatigue, proneness to infections and proneness
to stress.
A dichotomized diagnostic statement for both Prognos® tests
was available for 72 participants (22 cases, 25 healthy amal-
gam bearer, and 25 amalgam-free volunteers). There was no
agreement above chance between the dichotomized findings
(amalgam burden yes/no) in the first and the second Prognos®
test (Cohen’s Kappa = –0.11, p = 0.30). Of the 33 participants
classified as amalgam burdened at the first test, 14 (42%) were
classified as not amalgam burdened at the second, and of the
39 tested not amalgam burdened at the first test 27 (69%)
were classified amalgam burdened at the second. Comparing
the Prognos® sum scores of the two diagnostic sessions against
each other provided a similar result (intraclass correlation
coefficient = –0.01, 95% confidence interval –0.24 to 0.22; 
p = 0.53; fig. 2). Agreement for the 6 single substance tests 
was poor with intraclass correlation coefficients of 0.05 (95%
confidence interval –0.19 to 0.28) for Amalgam D10; of 0.08
(–0.15 to 0.31) for Amalgam D200; of –0.05 (–0.28 to 0.18) for
Amalgam pure; of 0.04 (–0.19 to 0.27) for Chlorella; of –0.08
(–0.31 to 0.15) for Coriander; and of –0.22 (-0.43 to 0.01) for
Toxinex.
Prognos® sum scores and findings for single substance tests
did not differ significantly between cases and controls (fig. 3;
table 2). In contrast, significant differences between the three
groups were found for urine measurements before and after
Dimaval® (mercury in total), blood measurements (inorganic
mercury, particularly in plasma), and saliva (table 3). Pairwise
comparisons revealed that significant differences were always
due to lower mercury or amalgam burden in amalgam-free
healthy volunteers while the results in healthy amalgam bear-
ers and cases were similar. The LTT was not able to discrimi-
nate between the three groups. There was no correlation be-
tween the Prognos® sum score of the first session and the
combination score of mercury mobilization after Dimaval®
and mercury in saliva after chewing gum (Spearman correla-
tion coefficient = 0.14; p = 0.22). Correlations between the sin-
gle Prognos® substance tests were low (<0.3) to moderate
(maximum value 0.43), correlations with measurements in
blood, urine and saliva low (<0.3; table 4).
Discussion
The main findings of the study can be summarized as follows:
(1) There was no agreement above chance between the find-
ings of two diagnostic sessions with the Prognos® device; (2)
Prognos® sum scores did not differ in a significant manner be-
tween groups, while amalgam-free healthy volunteers had sig-
nificantly lower mercury levels in blood, urine and saliva; (3)
there were no significant differences between patients with
suspected amalgam hypersensitivity and healthy amalgam
bearers in any test; (4) there was no correlations between
Prognos® findings and other diagnostic tests.
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Amalgam Healthy amalgam Healthy amalgam- p-value
hypersensitive participants free participants
participants
Total Hg in saliva before chewing gum (ng/ml) 1.10 (1.70) 1.28 (1.67) 0.04 (0.03) <0.001
Total Hg in saliva after chewing gum (ng/ml) 1.04 (0.78) 1.38 (1.79) 0.02 (0.04) <0.001
Total Hg in saliva before chewing gum (ng) 3.92 (6.83) 5.07 (7.27) 0.16 (0.16) <0.001
Total Hg in saliva after chewing gum (ng) 3.58 (3.19) 5.31 (7.26) 0.08 (0.16) <0.001
Inorganic Hg in erthrocytes (ng/ml) 0.43 (0.36) 0.43 (0.35) 0.10 (0.05) <0.001
Inorganic Hg in plasma (ng/ml) 0.49 (0.44) 0.44 (0.34) 0.08 (0.05) <0.001
Total Hg in urine before Dimaval® (ng/ml) 0.65 (0.68) 0.77 (0.70) 0.19 (0.14) <0.001
Total Hg in urine after Dimaval® (ng/ml) 4.26 (5.35) 5.71(5.45) 0.89 (0.92) <0.001
Total Hg in urine before Dimaval® (µg/24h) 0.98 (0.92) 1.19 (1.03) 0.26 (0.19) <0.001
Total Hg in urine after Dimaval® (µg /24h) 7.77 (10.20) 12.69 (18.60) 1.43 (1.45) <0.001
Combination score total mercury in urine after 
DMPS + total Hg in saliva after chewing gum 11.12 (4.09) 12.37 (3.70) 3.44 (2.03) <0.001
LTT inorganic Hg (stimulation index) 3.20 (4.26) 3.23 (3.31) 3.18 (3.96) <0.48
LTT amalgam (stimulation index) 1.94 (1.28) 2.12 (1.87) 1.74 (0.68) <0.86
Table 3. Diagnostic
test results: values
are means (sd), p-va-
lues from Kruskal-
Wallis test (Hg =
mercury)
Strengths and Limitations
Strengths of our study include a design with both healthy
amalgam bearers and amalgam-free subjects as controls, strict
blinding of diagnostic assessments, and inclusion of a variety
of methods used for identification of amalgam burden or
amalgam hypersensitivity. Most of these methods were direct-
ly compared for the first time.
When interpreting the findings of our study some limitations
have to be taken into account: (1) We cannot rule out that the
mobilization of mercury between the first and the second
Prognos® test interfered with the Prognos® measurements.
However, it is very unlikely that the lack of agreement be-
tween first and second Prognos® tests can only be attributed
to the influence of the small diagnostic dose of 300 mg of Di-
maval®. (2) The researcher who did the Prognos® testing
(WK) was a novice. On the other hand, he was trained by the
expert evaluating the findings until his training and perfor-
mance were considered adequate. (3) The decision to choose a
summarized score of all tested Prognos® substances as a main
outcome measure was not founded on empirical evidence but
on the Prognos® expert’s assumption that this score might be
particularly sensitive. Based on our results it might be justified
to examine only the scores for Amalgam D10 and Amalgam
pure as main outcome measures in future studies. According
to the Prognos® expert regarding Amalgam D10 a possible ex-
planation might be that it contains amalgam in a concentra-
tion similar to the average rate released by amalgam fillings
whereas amalgam pure represents an acute intoxication. How-
ever, agreement for measurements obtained at the two sepa-
rate sessions was poor not only for the summary score but also
for all single substance tests including those for Amalgam D10
and Amalgam pure. (4) A major problem is, of course, that it
is unclear whether all subjects classified as cases are true amal-
gam sensitives. As there is no gold standard diagnostic test for
this problem and controversy whether this condition exists at
all, our study is not a direct validity test. However, it seems
plausible to expect that a valid diagnostic tool should at least
separate amalgam-free subjects from amalgam bearers. (5)
Our cases and controls differed in a variety of aspects such as
age or sex. However, such differences would be expected to
cause, if anything, an overestimation of the agreement.
Interpretation
A variety of unconventional diagnostic methods are used to
test for amalgam hypersensitivity like bioresonance and kine-
siology. Although other methods might be applied more fre-
quently, we chose to use Prognos® in our evaluation as (1)
there is evidence that the measurement of skin resistance with
Prognos® produces reliable findings [6, 7]; (2) the diagnostic
process can be standardized and allows blinded assessments;
(3) Prognos® experts provided operationalized hypotheses. 
How can we explain the discrepant findings regarding reliabil-
ity in previous studies and regarding agreement in our investi-
gation? Treugut et al. [6] and Colbert et al. [7] determined the
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reliability of the direct measurements of electrical skin resis-
tance at the meridian points. The measurements taken in these
studies correspond to the first ‘main’ measurement in our
study (without stimulation or any substances). Measurements
were repeated within a short time period. In our study there
were several days up to weeks between the two measurement
sessions. Instead of ‘raw’ skin resistance measurements we
used ‘integrated diagnostic’ values synthesized by the Prog-
nos® computer software from measurements at all relevant
meridian points with substance testing and compared them
with the first ‘main’ measurement. On which level reliability is
actually lost remains unclear.
We are not aware of other empirical investigations of the reli-
ability and validity of Prognos® beyond skin-resistance mea-
surement in the peer-reviewed literature. In an unpublished
open study the Prognos® expert of our team found good
agreement of Prognos® findings with conventional thyroid
function tests. Rigorous studies are clearly desirable. Future
diagnostic studies to test validity should preferably be per-
formed in conditions for which an established gold standard
diagnostic test exists. Reliability must be tested both at the
level of electrical skin measurements and at the level of clini-
cal statements.
The diagnosis of amalgam hypersensitivity is a highly contro-
versial issue. If one or several of the diagnostic tools tested in
our study would have reliably discriminated between cases
and controls this would have been indirect evidence that amal-
gam sensitivity is a valid pathological concept. However, the
diagnostic methods were only able to detect differences be-
tween amalgam-free subjects and amalgam bearers (regard-
less of their health condition). While our results do not pro-
vide support for the concept of amalgam hypersensitivity, it
can, of course, not be ruled out, that it is a valid concept.
It is difficult to make recommendations for studies on further
diagnostic tools for amalgam hypersensitivity used by practi-
tioners of complementary and alternative medicine. As it is
relatively easy to study reliability this should be investigated
first. A diagnostic tool which is unreliable is also unlikely to
produce valid findings. If a diagnostic tool has been shown,
however, to be reliable, we think that indirect validation
strategies as used in our study are the only option to proceed. 
Conclusion
In this study Prognos® could not be shown to be a useful tool
in the diagnosis of disorders suspected to be due to dental
amalgam fillings. It is not possible to extrapolate on the relia-
bility and validity of Prognos® as diagnostic device for other
conditions from our results.
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